Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6911)	5/27/2003 11:09:08 PM
From: John Metcalf	Respond to of 10280

"My guess is that today was just a rumor by someone trying to squeeze a short or two." Shorts must have been running during the recent rally. On the April report date (4-16?), SEPR was at $16.78. Much of the 40% run-up since then must have been fueled by short-covering. OTOH, short interest increased about 12% from March (3-14?) at $12.99 to April at $16.78. During that time, shorts increased while the shares gained 29%. Could there be that many short-sellers who are doubling up? Seems counter-intuitive.

To: Biomaven who wrote (6911)	5/28/2003 1:31:26 AM
From: Icebrg	Read Replies (1) \| Respond to of 10280

>>They could abandon Claritin, let Clarinex go OTC and finally keep Soltara as their prescription drug I'd be very surprised indeed if this were to happen. SGP isn't going to give up the 20+% of the antihistamine market held by Clarinex in exchange for a not-yet-approved drug. Also, the FTC would need quite a bit of convincing, which would cause unacceptable delay. >> You are right. I thought that they could wait with the disposal until they actually had the approval. There should be no logic reason for FTC to demand that they give up a drug they cannot sell yet. But considering how things actually are done - latest demonstrated in the Pfizer/Pharmacia merger with the two ED-drugs Pfizer had to give up - it appears that it doesn't matter if a drug is under development or not. Erik